Mathes Company’s Immix Biopharma IMMX Stock Holding History

Mathes Company’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Hold	10,650	–	–	0.03%	129
2026 Q1	$97K	Hold	10,650	–	–	0.04%	126
2025 Q4	$56K	Buy	+10,650	New	+$43.8K	0.02%	126

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mathes Company's IMMX Position: Q2 2026 in Review

Mathes Company held its Immix Biopharma (IMMX) position steady in Q2 2026 at 10,650 shares worth $110K. The position accounts for 0.03% of the portfolio, ranked #129.

Mathes Company first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Mathes Company held 10,650 shares of Immix Biopharma worth $110K as of Q2 2026.
Mathes Company left its Immix Biopharma share count unchanged in Q2 2026.
Immix Biopharma made up 0.03% of Mathes Company's portfolio in Q2 2026, its #129 holding.
Mathes Company first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Mathes Company's 13F filing for Q2 2026, filed 11 Aug 2026.